Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
$130.00 16 in stock Retatrutide is a next-generation GLP-1/GIP/glucagon triple receptor agonist developed by Eli Lilly
In Phase 2 trials involving 338 participants across all doses, 88.8% of patients at the 12mg dose successfully completed the 48-week study despite experiencing side effects
Once youve been assessed and approved by our medical provider, you are committed to either a 6-month plan, and early cancellations or refunds are not available
J Mater Chem B 9:34233449 Liu Y, Jiang T, Liu Z (2022) Metal-organic frameworks for bioimaging: strategies and challenges
US$ 25.37
US$ 29.53
US$ 24.94
US$ 27.64
